GHRP-6 at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
GHRP-6 is a synthetic hexapeptide and the first widely studied ghrelin receptor agonist. Developed in the 1980s at Tulane University by Cyril Bowers, it served as the prototype for an entire class of GH secretagogues and established the proof of concept that the ghrelin receptor could be pharmacologically targeted to stimulate GH release.
Compared to newer GH secretagogues like ipamorelin and GHRP-2, GHRP-6 produces the most pronounced appetite stimulation - a direct consequence of its ghrelin mimetic activity in the hypothalamus. This property limits its utility in fat loss protocols but makes it valuable for individuals seeking to increase caloric intake alongside GH optimization (e.g., bulking phases or recovery from illness-related muscle wasting).
GHRP-6 also exhibits gastrointestinal motility effects mediated through GHS-R1a receptors in the gut, which has led to research interest in conditions like gastroparesis. Receptor desensitization occurs with continuous use, and cycling or rotating with other secretagogues is commonly recommended.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.